Corvus Pharmaceuticals announced data from a preclinical study of CPI-818, its investigational small molecule T-cell signaling pathway inhibitor. Study results indicated that orally-administered CPI-818 produced tumor regression in three of three companion dogs with spontaneous, naturally occurring T-cell lymphomas, without significant toxicity. These preclinical data are being presented in a poster at the T-cell Lymphoma Forum. Based on these data, Corvus plans to submit an investigational new drug, or IND, application with the FDA in early 2019. The company plans to evaluate CPI-818 in a Phase 1/1b study in patients with several types of T-cell lymphomas, including peripheral T-cell lymphoma, cutaneous T-cell lymphoma and others. Data demonstrated cytotoxicity against several types of human and mouse T-cell lymphomas at concentrations that do not harm normal T-cells. Also, data showed evidence of Th1 skewing in human and mouse lymphocytes, indicating that CPI-818 induced the differentiation of T-cells to cytotoxic T-cells, which is thought to be an important component of the immune system’s destruction of cancer cells.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.